Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Ipsen Stock News

IPSEFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$113.13

Last update: Dec 31, 7:00 PM

Ipsen (IPSEF) Forecast

News

Earnings Ipsen (IPSEF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Ipsen Stock News | OTC:IPSEF | Benzinga

Get the latest news on Ipsen stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Ipsen performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, June 11, 2024

FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo
Shivani Kumaresan

Tuesday, April 02, 2024

Ipsen And Sutro Biopharma Enter Exclusive Glo...
Benzinga Newsdesk

Wednesday, March 27, 2024

Merrimack Secures $225M Milestone Payment Fro...
Benzinga Newsdesk

Monday, August 21, 2023

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Vandana Singh

Monday, May 22, 2023

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
Vandana Singh

Monday, January 09, 2023

France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
Vandana Singh

Wednesday, November 09, 2022

Why Merrimack Shares Are Surging Over 200% Today?
Vandana Singh

Wednesday, August 03, 2022

Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
Vandana Singh

Monday, June 27, 2022

Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Vandana Singh

Tuesday, May 03, 2022

Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
Vandana Singh

Friday, March 25, 2022

EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
Vandana Singh

Monday, January 24, 2022

Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease
Vandana Singh

Friday, December 17, 2021

Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
Vandana Singh

Friday, August 13, 2021

Ipsen Stock Declines After Pulling Rare Disease Application
Vandana Singh

Monday, August 02, 2021

Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders
Vandana Singh

Monday, June 28, 2021

Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Vandana Singh

Friday, February 26, 2021

European Medicines Agency's CHMP Backs Approval Of Cabometyx/Opdivo Combo In Kidney Cancer
Vandana Singh

Tuesday, August 30, 2011

Earnings Roundup
Benzinga
Ipsen Reports 21% Surge In First-Half Net Income
Benzinga

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved